Prevention and treatment of amyloidogenic disease
First Claim
Patent Images
1. A method of therapeutically treating a disease characterized by an amyloid deposit of Aβ
- in a patient having the disease, comprising;
administering an effective dose of a polypeptide comprising an immunogenic fragment of Aβ
(SEQ ID NO;
1) and an adjuvant in a regime effective to induce an immune response comprising antibodies to the Aβ
fragment, the adjuvant enhancing the immune response to the Aβ
fragment, and thereby therapeutically treat the disease in the patient.
7 Assignments
0 Petitions
Accused Products
Abstract
The invention provides compositions and methods for treatment of amyloidogenic diseases. Such methods entail administering an agent that induces a beneficial immune response against an amyloid deposit in the patient. The methods are particularly useful for prophylactic and therapeutic treatment of Alzheimer'"'"'s disease. In such methods, a suitable agent is Aβ peptide or an antibody thereto.
-
Citations
120 Claims
-
1. A method of therapeutically treating a disease characterized by an amyloid deposit of Aβ
- in a patient having the disease, comprising;
administering an effective dose of a polypeptide comprising an immunogenic fragment of Aβ
(SEQ ID NO;
1) and an adjuvant in a regime effective to induce an immune response comprising antibodies to the Aβ
fragment, the adjuvant enhancing the immune response to the Aβ
fragment, and thereby therapeutically treat the disease in the patient. - View Dependent Claims (2, 3, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34)
- in a patient having the disease, comprising;
-
4. The method of claim l, wherein the disease is Alzheimer'"'"'s disease.
-
35. A method of therapeutically treating a disease characterized by an amyloid deposit of Aβ
- in a patient having the disease, comprising;
administering an immunogenic fragment of Aβ
peptide (SEQ ID NO;
1) in a regime effective to induce an immune response comprising antibodies to the Aβ
fragment and thereby therapeutically treat the disease in the patient, wherein the dose of the Aβ
fragment administered to the patient at least 50 μ
g. - View Dependent Claims (36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48)
- in a patient having the disease, comprising;
-
49. A method of therapeutically treating a disease characterized by an amyloid deposit of Aβ
- in a patient, comprising;
administering an Aβ
fragment (SEQ ID NO;
1) in a regime effective to induce an immune response comprising antibodies to the Aβ
fragment and thereby therapeutically treat the disease in the patient; and
monitoring the patient for the immune response, wherein the monitoring comprises detecting antibodies having Aβ
fragment binding specificity. - View Dependent Claims (50)
- in a patient, comprising;
-
51. A method of prophylactically a disease characterized by an amyloid deposit of Aβ
- in a patient susceptible to the disease, comprising;
administering an effective dose of a polypeptide comprising an immunogenic fragment of Aβ
(SEQ ID NO;
1) and an adjuvant in a regime effective to induce an immune response comprising antibodies to the Aβ
fragment, the adjuvant enhancing the immune response to the Aβ
fragment, and thereby prophylactically treat the disease in the patient. - View Dependent Claims (52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85)
- in a patient susceptible to the disease, comprising;
-
86. A method of prophylactically treating a disease characterized by an amyloid deposit of Aβ
- in a patient, comprising;
administering an immunogenic fragment of Aβ
peptide (SEQ ID NO;
1) in a regime effective to induce an immune response comprising antibodies to the Aβ
fragment and thereby prophylactically treat the disease in the patient, wherein the dose of the Aβ
fragment administered to the patient at least 50 μ
g. - View Dependent Claims (87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100)
- in a patient, comprising;
-
101. A method of prophylactically treating a disease characterized by an amyloid deposit of Aβ
- in a patient susceptible to the disease, comprising;
administering an Aβ
fragment (SEQ ID NO;
1) in a regime effective to induce an immune response comprising antibodies to the Aβ
fragment and thereby prophylactically or therapeutically treat the disease in the patient; and
monitoring the patient for the immune response, wherein the monitoring comprises detecting antibodies having Aβ
fragment binding specificity. - View Dependent Claims (102)
- in a patient susceptible to the disease, comprising;
-
103. A pharmaceutical composition comprising an immunogenic fragment of Aβ
- (SEQ ID NO;
1) and a pharmaceutically acceptable adjuvant effective to induce an immune response comprising antibodies to the Aβ
fragment, wherein the adjuvant enhances the immune to the Aβ
fragment. - View Dependent Claims (104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120)
- (SEQ ID NO;
Specification